Home » Stocks » Parnell Pharmaceuticals Holdings

Parnell Pharmaceuticals Holdings Ltd. (PARNF)

Stock Price: $0.101 USD 0.000 (0.00%)
Updated Oct 16, 2020 3:33 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 1.83M
Revenue (ttm) 276,171
Net Income (ttm) -24,441
Shares Out 18.15M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 16, 2020
Last Price $0.101
Previous Close $0.101
Change ($) 0.000
Change (%) 0.00%
Day's Open 0.128
Day's Range 0.101 - 0.128
Day's Volume 1,700
52-Week Range 0.04 - 0.35

More Stats

Market Cap 1.83M
Enterprise Value n/a
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 18.15M
Float 10.23M
EPS (basic) n/a
EPS (diluted) -1.05
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 27,414
Short Ratio 0.29
Short % of Float 0.27%
Beta 3.22
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 6.64
PB Ratio n/a
Revenue 276,171
Operating Income n/a
Net Income -24,441
Free Cash Flow n/a
Net Cash n/a
Net Cash / Share n/a
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA 4.11%
ROE n/a
ROIC n/a
Key stats in USD, based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$11.11*
Low
11.1
Current: $0.101
High
11.1
Target: 11.11
*Average 12-month USD price target from 1 stock analysts.

Financial Performance

Financial Overview

No financial data available for this stock yet.

Company Profile

Company Details

Full Name Parnell Pharmaceuticals Holdings Ltd.
CEO Brad R. McCarthy

Stock Information

Ticker Symbol PARNF
Stock Exchange US OTC
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier OTCMKTS: PARNF
IPO Date June 18, 2014

Description

Parnell Pharmaceuticals Holdings Ltd, a veterinary pharmaceutical company, focuses on developing, manufacturing, and commercializing various animal health solutions. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for improving cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product aids in the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also operates mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.